Aptn

앱튼 · 270520

Industrials Construction & Engineering · KOSDAQ

Small-cap

Market cap US$15.6M (₩21.5B)

Overview

Aptn is developing a new drug aimed at treating Parkinson's disease, a progressive neurological condition caused by the loss of dopamine-producing brain cells.

The intended users are Parkinson's patients, particularly older adults for whom existing standard therapies offer only symptom relief and carry significant long-term side effects. Listed on KOSDAQ, Korea's tech and small-cap board, the company is expanding into the brain-disease treatment field by acquiring foundational technology rights and establishing a dedicated neurological-drug division.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$12.2M

▼ −8.1% YoY

Operating profit · FY2025

−US$8.1M

Loss narrowed

Net income · FY2025

−US$17M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$14.8M(₩20.4B)	US$13.3M(₩18.4B)	US$12.2M(₩16.9B)
Operating profit	−US$4.7M(−₩6.5B)	−US$9.2M(−₩12.8B)	−US$8.1M(−₩11.2B)
Net income	−US$3.6M(−₩5B)	−US$13.9M(−₩19.2B)	−US$17M(−₩23.4B)

Revenue

FY2023US$14.8M
FY2024US$13.3M
FY2025US$12.2M

Operating profit

FY2023−US$4.7M
FY2024−US$9.2M
FY2025−US$8.1M

Net income

FY2023−US$3.6M
FY2024−US$13.9M
FY2025−US$17M

Key ratios (FY2025)

ROE

-24.6%

Debt/Eq

68.2%

Op. margin

-66.0%

Net margin

-138.7%

Rev. YoY

▼ −8.1%

Why it matters

Aptn acquired its core Parkinson's disease technology rights from Seoul National University's industry-academic cooperation foundation, which is the stated origin of its drug-development programme.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?